JUNS Stock Analysis: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$0.28
0.04 (18.34%)
▲
5d:
+17.65%
30d:
+16.72%
90d:
-19.77%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 17, 2026
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: JUNS shows positive signals but monitor for confirmation. Market pricing in 21.0% decline. Moderate conviction.
💡 BUY OPPORTUNITY: JUNS shows positive signals but monitor for confirmation. Market pricing in 21.0% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $0.28, which is considered extended relative to its 30-day fair value range of $0.22 to $0.28. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.7) compared to its historical average (9.5). Remarkably, the market is currently pricing in an annual earnings decline of 21.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.29. The stock is showing strong short-term momentum, up 18.3% recently.
Market Sentiment: JUNS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+10614.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.29. The stock is showing strong short-term momentum, up 18.3% recently.
Market Sentiment: JUNS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+10614.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.22 -
$0.28
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+18.3%)
- BULLISH: Trading 10614.3% below Wall St target ($30.00)
Trading Range Analysis
30-Day Trading Range
$0.22 -
$0.28
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.22
Resistance Level
$0.29
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.67
Wall Street Target
$30.00
(+10614.3%)
Valuation Discount vs History
-21.0% cheaper
PE vs Historical
4.7 vs 9.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-21.0%
(market-implied from PE analysis)
1-Year Target
$0.25
(-10%)
2-Year Target
$0.23
(-19%)
3-Year Target
$0.20
(-27%)
3-Yr Target (if PE normalizes)
(PE: 5→10)
$0.42
(+48%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.7 to 9.5
Stabilization Target:
$0.57
(+103.6%)
PE Expansion Potential:
+103.6%
Share & Embed Analysis
Last updated: June 27, 2026 2:57 PM ET
Data refreshes hourly during market hours. Next update: 3:57 PM
Data refreshes hourly during market hours. Next update: 3:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 67 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 60 HOLD |
